Drug Profile
COVID-2019 infections vaccine - Generex Biotechnology
Alternative Names: 'Ii-Key-nCOV peptide vaccine - Generex Biotechnology; Complete Vaccine™ - Generex Biotechnology; Coronavirus vaccine - Generex Biotechnology; Ii-Key-SARS-CoV-2 vaccine; SARS-CoV-2 virus vaccines - Generex BiotechnologyLatest Information Update: 05 May 2021
Price :
$50
*
At a glance
- Originator Generex Biotechnology Corporation
- Class COVID-19 vaccines; Peptide vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 27 Apr 2021 Generex Biotechnology Corporation announces intention to submit IND application to National Medical Products Administration (NMPA) for COVID-2019 infections
- 24 Feb 2021 Immunogenicity data from a preclinical trial in COVID-2019 infection released by Generex Biotechnology
- 24 Feb 2021 Generex Biotechnology plans a clinical trial in COVID-2019 infections (Prevention) (previously infected)